Vorobeva Elena V, Kyyaly M Aref, Sones Collin L, He Peijun J W, Arshad S Hasan, Sanchez-Elsner Tilman, Kurukulaaratchy Ramesh J
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Biomedical Science, Department of Science and Engineering, Solent University Southampton, Southampton SO14 0YN, UK.
Int J Mol Sci. 2025 Jul 11;26(14):6676. doi: 10.3390/ijms26146676.
Asthma places a significant burden at individual and societal levels, but there remains no gold-standard objective test for asthma diagnosis or asthma severity risk prediction. MicroRNAs (miRNAs) are short non-coding RNA sequences that are attracting interest as biological signatures of health and disease status. We sought to construct serum miRNA panels that could serve as potential biomarkers to aid in the diagnosis of asthma and predict asthma severity. Thirty-five asthma-related miRNAs were screened in the serum of three patient groups (never-asthma, mild-asthma, and severe-asthma; = 50/group) drawn from two well-characterised cohorts. miRCURY LNA technology was used, followed by GeneGlobe analysis. The associations of miRNA expression with clinical outcomes of interest and diagnostic value of the proposed miRNA panels were assessed. We identified an asthma diagnosis panel comprising upregulated miR-223-3p, miR-191-5p, and miR-197-3p (area under curve (AUC) = 0.813, sensitivity 76% and specificity 72%). Compared with mild-asthma individuals, we also identified an asthma severity risk panel comprising upregulated miR-223-3p plus downregulated miR-30a-5p, miR-660-5p, and miR-125b-5p (AUC = 0.759, sensitivity 78%, specificity 64%). Individual miRNAs showed associations with worse clinical asthma severity and impaired quality of life. miRNA panels with high sensitivity and specificity offer potential as biomarkers for asthma diagnosis and asthma severity.
哮喘在个人和社会层面都带来了沉重负担，但目前仍没有用于哮喘诊断或哮喘严重程度风险预测的金标准客观测试。微小RNA（miRNA）是短的非编码RNA序列，作为健康和疾病状态的生物学标志正引起人们的关注。我们试图构建血清miRNA组合，作为潜在的生物标志物，以辅助哮喘诊断并预测哮喘严重程度。在来自两个特征明确队列的三组患者（非哮喘组、轻度哮喘组和重度哮喘组；每组n = 50）的血清中筛选了35种与哮喘相关的miRNA。采用miRCURY LNA技术，随后进行GeneGlobe分析。评估了miRNA表达与感兴趣的临床结果之间的关联以及所提出的miRNA组合的诊断价值。我们确定了一个哮喘诊断组合，包括上调的miR-223-3p、miR-191-5p和miR-197-3p（曲线下面积（AUC）= 0.813，敏感性76%，特异性72%）。与轻度哮喘个体相比，我们还确定了一个哮喘严重程度风险组合，包括上调的miR-223-3p加上下调的miR-30a-5p、miR-660-5p和miR-125b-5p（AUC = 0.759，敏感性78%，特异性64%）。单个miRNA与更差的临床哮喘严重程度和生活质量受损相关。具有高敏感性和特异性的miRNA组合有望作为哮喘诊断和哮喘严重程度的生物标志物。
